Methods for treatment of diseases
The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.
1. A method of reducing tissue damage or toxicity resulting from radiation therapy, chemotherapy or a combination thereof, the tissue damage or toxicity being modulated by superoxide activity in a human patient, the method comprising parenterally administering to the patient 75 to 450 mg of a superoxide dismutase mimetic within a period of 60 minutes, wherein the superoxide dismutase mimetic corresponds to Formula (GC4419):
wherein X and Y are independently neutral or negatively-charged ligands.
2. The method of claim 1 , wherein the method comprises administering to the patient the superoxide dismutase mimetic to provide an exposure as measured by an area under the curve (AUC) of at least 4,000 ng-h/mL as calculated from measurement of the superoxide dismutase mimetic concentration in the patient's plasma.
3. The method of claim 1 , wherein the superoxide dismutase mimetic is administered intravenously.
4. The method of claim 1 , wherein the superoxide dismutase mimetic is administered as a pharmaceutical composition comprising the superoxide dismutase mimetic corresponding to Formula (GC4419) and a pharmaceutically acceptable carrier.
5. The method of claim 1 , wherein the superoxide dismutase mimetic is administered in the form of a unit dose formulation.
6. The method of claim 1 , wherein the superoxide dismutase mimetic is dissolved in a solution comprising 0.25 mg/mL to 3.5 mg/mL superoxide dismutase mimetic and contained in an IV bag.
7. The method of claim 1 , wherein X and Y are independently selected from monodentate ligands.
8. The method of claim 1 , wherein X and Y are independently selected from the group consisting of aquo ligands, halo ligands, carboxylate ligands, and bicarbonate ligands.
9. The method of claim 1 , wherein X and Y are chloro ligands.
10. The method of claim 1 , wherein the method comprises administering to the patient at least 100 mg of a superoxide dismutase mimetic.
11. The method of claim 1 , wherein the method comprises administering superoxide dismutase mimetic to the patient at a rate of 200 mg/hr.
12. The method of claim 1 , wherein the method comprises administering superoxide dismutase mimetic to the patient at a rate of 450 mg/hr.
13. The method of claim 1 , wherein the superoxide dismutase mimetic is administered to the patient prior to or simultaneous with the radiation therapy or chemotherapy.
14. The method of claim 1 , wherein the superoxide dismutase mimetic is administered to the patient prior to, but not after, the radiation therapy or chemotherapy.
15. The method of claim 1 wherein the superoxide dismutase mimetic is administered to the patient at least 30 minutes prior to the radiation therapy or chemotherapy.
16. The method of claim 1 , wherein the superoxide dismutase mimetic is administered to the patient after the radiation therapy or chemotherapy.
17. The method of claim 1 , wherein the superoxide dismutase mimetic is administered to the patient up to twelve weeks after the radiation therapy or chemotherapy.